Format

Send to

Choose Destination
See comment in PubMed Commons below
Brain Imaging Behav. 2011 Sep;5(3):203-11. doi: 10.1007/s11682-011-9124-5.

A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.

Author information

1
William S. Middleton Memorial Veterans Hospital, Madison, WI 53792, USA. gallagher@neurology.wisc.edu

Abstract

Although [(18)F]fluoro-L: -dopa [FDOPA] positron emission tomography (PET) has been used as a surrogate outcome measure in Parkinson's disease therapeutic trials, this biomarker has not been proven to reflect clinical status longitudinally. We completed a retrospective analysis of relationships between computerized sampling of motor performance, FDOPA PET, and clinical outcome scales, repeated over 4 years, in 26 Parkinson's disease (PD) patients and 11 healthy controls. Mixed effects analyses showed that movement time and tongue strength best differentiated PD from control subjects. In the treated PD cohort, motor performance measures changed gradually in contrast to a steady decline in striatal FDOPA uptake. Prolonged reaction and movement time were related to lower caudate nucleus FDOPA uptake, and abnormalities in hand fine force control were related to mean striatal FDOPA uptake. These findings provide evidence that regional loss of nigrostriatal inputs to frontostriatal networks affects specific aspects of motor function.

PMID:
21556744
PMCID:
PMC3150388
DOI:
10.1007/s11682-011-9124-5
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center